Physician profile
Lawrence Deck
NPI 1467495911
$5,500.04
in general payments reported to CMS, 2019-2025
34 companies · $67.87 in 2025
The $67.87 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,534 · 2020: $706 · 2021: $750 · 2022: $429 · 2023: $436 · 2024: $576 · 2025: $67.87.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $958 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $122.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $958.20 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $122.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $999.97 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $546.11 | 2019-2021 | |
| Amgen INC. | $379.77 | 2019-2025 | Evenity, Prolia |
| Eisai INC. | $320.14 | 2021-2025 | |
| Novo Nordisk INC | $274.70 | 2019-2024 | Wegovy |
| Esperion Therapeutics, INC. | $249.66 | 2021 | |
| Allergan, INC. | $243.07 | 2019-2020 | |
| Amarin Pharma, INC. | $231.39 | 2019 | |
| Astellas Pharma US INC | $147.31 | 2019-2023 | Veozah |
| Antares Pharma, INC. | $141.76 | 2023-2024 | Xyosted, Tlando |
| Novartis Pharmaceuticals Corporation | $126.30 | 2022 | |
| Regeneron Pharmaceuticals, INC. | $125.11 | 2019 | |
| Sanofi-Aventis U.S. LLC | $124.99 | 2019 | |
| Corcept Therapeutics | $124.37 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $123.11 | 2019 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medicure Pharma INC. | $122.34 | 2024 | Zypitamag |
| Astrazeneca Pharmaceuticals Lp | $117.32 | 2022 | |
| Rhythm Pharmaceuticals, INC. | $114.59 | 2023 | Imcivree |
| Regeneron Healthcare Solutions, INC. | $114.59 | 2024 | Evkeeza |
| Celgene Corporation | $114.51 | 2019 | |
| Althera Pharmaceuticals LLC | $105.00 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $98.53 | 2019 | |
| Lilly USA, LLC | $91.37 | 2019 | |
| Abbott Laboratories | $80.08 | 2022 | |
| Pfizer INC. | $58.45 | 2020-2021 | |
| Radius Health, INC. | $58.18 | 2020-2021 | |
| Amneal Pharmaceuticals LLC | $55.41 | 2024 | Unithroid |
| Boston Scientific Corporation | $46.17 | 2023 | |
| Glaxosmithkline, LLC. | $43.22 | 2021-2024 | Arexvy, Trelegy Ellipta |
| Exactech, INC. | $33.89 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $23.64 | 2023 | |
| Alfasigma USA, INC. | $22.05 | 2021 | |
| Exact Sciences Corporation | $21.50 | 2025 | Cologuard Collection Kit |
| Nestle Healthcare Nutrition INC. | $21.44 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Deck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.